ScoreWhy is Dr Lal Pathlabs Ltd ?
1
Poor long term growth as Net Sales has grown by an annual rate of 14.39% and Operating profit at 19.92% over the last 5 years
2
With ROE of 22.4, it has a Very Expensive valuation with a 10.1 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -5.48%, its profits have risen by 33.1% ; the PEG ratio of the company is 1.4
3
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -0.58% over the previous quarter and currently hold 53.21% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -5.48% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Healthcare Services)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Dr Lal Pathlabs for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Dr Lal Pathlabs
-5.43%
-0.20
27.43%
Sensex
4.89%
0.41
11.85%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
14.39%
EBIT Growth (5y)
19.92%
EBIT to Interest (avg)
19.95
Debt to EBITDA (avg)
0.42
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
1.10
Tax Ratio
20.20%
Dividend Payout Ratio
42.00%
Pledged Shares
0
Institutional Holding
40.35%
ROCE (avg)
60.59%
ROE (avg)
20.98%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
45
Industry P/E
61
Price to Book Value
10.08
EV to EBIT
38.69
EV to EBITDA
31.00
EV to Capital Employed
18.45
EV to Sales
8.82
PEG Ratio
1.37
Dividend Yield
0.87%
ROCE (Latest)
47.69%
ROE (Latest)
22.38%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
PAT(Latest six months)
At Rs 282.80 cr has Grown at 20.03%
NET SALES(Q)
Highest at Rs 730.60 cr
PBDIT(Q)
Highest at Rs 224.10 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 30.67%
PBT LESS OI(Q)
Highest at Rs 178.80 cr.
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Dr Lal Pathlabs
Profit After Tax (PAT) - Latest six months
At Rs 282.80 cr has Grown at 20.03%
Year on Year (YoY)MOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 730.60 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 224.10 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 30.67%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 178.80 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
